TLTeresa Lee

Teresa Lee

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Teresa Lee has a total of 45 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Targeting O6-methylguanine-DNA Methyltransferase Deficiency in Preclinical Models of Extracranial Human Cancers with a Tumor-Selective DNA-Modifying Agent

    by Ranjini K. Sundaram, Spenser S. Johnson, Siddhant P. Bhoir, Vijay Menon, Kingson Lin, Collin D. Heer, Prateek Bhardwaj, Teresa Lee, Deepti Bhatt, Danielle M. Burgenske, et al.

    Temozolomide (TMZ) is an established therapy for gliomas with silencing of the DNA repair gene O6-methylguanine-DNA methyltransferase (MGMT) but is hindered by the frequent development of resistance via loss of mismatch repair (MMR) proteins. To overcome this resistance, a novel 2-fluoroethylating agent, KL-50, was designed to generate toxic DNA interstrand cross-links specifically in MGMT-deficient cells, bypassing MMR. KL-50 has shown efficacy in preclinical MGMT-silenced, TMZ-resistant glioma models. MGMT loss also occurs in a wide range of nonglioma cancers, but the ability of KL-50 to effectively treat these tumors with minimal off-target toxicity remains untested. In this study, we utilize a large-scale cell-line screen, focused panels of cancer cell lines, and tumor xenograft mouse models, including patient-derived xenografts, to interrogate the therapeutic potential of KL-50 in treating intracranial and extracranial tumors. We find that KL-50 is highly efficacious in a wide range of MGMT-deficient human tumor models, including colon cancer, melanoma, and lung cancer in vivo models. In addition, we demonstrate that KL-50 is impervious to loss of MMR and remains effective in tumors with induced TMZ resistance. Finally, we determine that KL-50 possesses higher MGMT selectivity in vitro compared with chloroethylating agents and is associated with less in vivo systemic toxicity in preclinical models. These results establish KL-50 as the first agent to maintain strong selectivity for MGMT loss while inducing tumor toxicity by an MMR-independent mechanism and support further development of 2-fluoroethylating agents for use in a tumor type–agnostic, biomarker-based strategy targeting MGMT-deficient tumors.

  • Intrathecal delivery of nanoparticle PARP inhibitor to the cerebrospinal fluid for the treatment of metastatic medulloblastoma

    by Minsoo Khang, Ju Hyun Lee, Teresa Lee, Hee-Won Suh, Supum Lee, Alessandra Cavaliere, Amy Rushing, Luiz H. Geraldo, Erika Belitzky, Samantha Rossano, et al.

    The morbidity associated with pediatric medulloblastoma, in particular in patients who develop leptomeningeal metastases, remains high in the absence of effective therapies. Administration of substances directly into the cerebrospinal fluid (CSF) is one approach to circumvent the blood-brain barrier and focus delivery of drugs to the site of tumor. However, high rates of CSF turnover prevent adequate drug accumulation and lead to rapid systemic clearance and toxicity. Here, we show that PLA-HPG nanoparticles, made with a single-emulsion, solvent evaporation process, can encapsulate talazoparib, a PARP inhibitor (BMN-673). These degradable polymer nanoparticles improve the therapeutic index when delivered intrathecally and lead to sustained drug retention in the tumor as measured with PET imaging and fluorescence microscopy. We demonstrate that administration of these particles into the CSF, alone or in combination with systemically administered temozolomide, is a highly effective therapy for tumor regression and prevention of leptomeningeal spread in xenograft mouse models of medulloblastoma. These results provide a rationale for harnessing nanoparticles for the delivery of drugs limited by brain penetration and therapeutic index and demonstrate important advantages in tolerability and efficacy for encapsulated drugs delivered locoregionally.


  • Top Cited Papers

    Polymer nanoparticles deliver mRNA to the lung for mucosal vaccination

    by Alexandra Suberi, Molly K. Grun, Tianyang Mao, Benjamin Israelow, Melanie Reschke, Julian Grundler, Laiba Akhtar, Teresa Lee, Kwangsoo Shin, Alexandra S. Piotrowski-Daspit, et al.

    An inhalable platform for messenger RNA (mRNA) therapeutics would enable minimally invasive and lung-targeted delivery for a host of pulmonary diseases. Development of lung-targeted mRNA therapeutics has been limited by poor transfection efficiency and risk of vehicle-induced pathology. Here, we report an inhalable polymer-based vehicle for delivery of therapeutic mRNAs to the lung. We optimized biodegradable poly(amine- co -ester) (PACE) polyplexes for mRNA delivery using end-group modifications and polyethylene glycol. These polyplexes achieved high transfection of mRNA throughout the lung, particularly in epithelial and antigen-presenting cells. We applied this technology to develop a mucosal vaccine for severe acute respiratory syndrome coronavirus 2 and found that intranasal vaccination with spike protein–encoding mRNA polyplexes induced potent cellular and humoral adaptive immunity and protected susceptible mice from lethal viral challenge. Together, these results demonstrate the translational potential of PACE polyplexes for therapeutic delivery of mRNA to the lungs.